Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS4235919 A
Publication typeGrant
Application numberUS 05/925,196
Publication dateNov 25, 1980
Filing dateJul 17, 1978
Priority dateJul 21, 1977
Publication number05925196, 925196, US 4235919 A, US 4235919A, US-A-4235919, US4235919 A, US4235919A
InventorsRichard Berthold
Original AssigneeSandoz Ltd.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Adrenergic blocking agents
US 4235919 A
Abstract
The compounds of formula I ##STR1## wherein R is a group ##STR2## wherein A is alkylene of 2 to 5 carbon atoms,
X is a bond, oxygen or sulfur,
R3 is hydrogen, hydroxy, alkoxy of 1 to 4 carbon atoms, halogen of atomic member of from 9 to 35, cyano, carbamoyl or a group NHCORd, wherein Rd is alkyl of 1 to 4 carbon atoms, and
R4 is hydrogen and, when R3 is alkoxy of 1 to 4 carbon atoms, R4 additionally may be alkoxy of 1 to 4 carbon atoms or, when R3 is halogen of atomic number of from 9 to 35, R4 additionally may be halogen of atomic number of from 9 to 35 either
(i) R1 is hydrogen or methyl and
R2 is cyano, CONRa Rb, COORc or CH2 ORe, wherein Ra, Rb, Rc and Re independently are hydrogen or alkyl of 1 to 4 carbon atoms,
or
(ii) either R1 is methyl and R2 is halogen of atomic number of from 17 to 35
or R1 is halogen of atomic number of from 17 to 35 and R2 is hydrogen or methyl,
with the provisos that
(a) X is separated from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain by at least 2 carbon atoms,
(b) when X is a bond, R3 is other than hydrogen and
(c) when R2 is cyano, R additionally may be alkyl of 3 to 7 carbon atoms,
are useful as α- and β-adrenoceptor blocking, antiarrhythmic and antihypertensive agents and as inhibitors of metabolic effects of emotional stress.
Images(14)
Previous page
Next page
Claims(38)
I claim:
1. A compound of formula I ##STR52## wherein R is a group ##STR53## wherein A is alkylene of 2 to 5 carbon atoms,
X is a bond, oxygen or sulfur,
R3 is hydrogen, hydroxy, alkoxy of 1 to 4 carbon atoms, halogen of atomic member of from 9 to 35, cyano, carbamoyl or a group NHCORd, wherein Rd is alkyl of 1 to 4 carbon atoms, and
R4 is hydrogen and, when R3 is alkoxy of 1 to 4 carbon atoms, R4 additionally may be alkoxy of 1 to 4 carbon atoms or, when R3 is halogen of atomic number of from 9 to 35, R4 additionally may be halogen of atomic number of from 9 to 35
either
(i) R1 is hydrogen or methyl and
R2 is cyano, CONRa Rb, COORc or CH2 ORe, wherein
Ra,Rb,Rc and Re independently are hydrogen or alkyl of 1 to 4 carbon atoms,
or
(ii) either R1 is methyl and R2 is halogen of atomic number of from 17 to 35
or
R1 is halogen of atomic number of from 17 to 35 and R2 is hydrogen or methyl,
with the provisos that
(a) X is separated from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain by at least 2 carbon atoms,
(b) when X is a bond, R3 is other than hydrogen and
(c) when R2 is cyano, R additionally may be alkyl of 3 to 7 carbon atoms,
in free form or in pharmaceutically acceptable salt form.
2. A pharmaceutical composition useful in treating vasoconstriction, arrhythmia, hypertension, and myocardial infarction comprising a therapeutically effective amount of a compound of claim 1, in association with a pharmaceutical carrier or diluent.
3. A method of treating diseases related to an adrenergic vasoconstriction, or coronary diseases, or diseases related to an inhibition of bowel motility, or arrhythmies, or hypertension, or lipolysis in the blood, hyperglycemia, appetite or myocardial infarction induced by emotional stress, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1.
4. A compound of claim 1 of formula Ix ##STR54## wherein Rx is a group ##STR55## wherein A is as defined above, either
(i) Xx is oxygen or sulfur and R1 x to R4 x have the significances indicated above for R1 to R4
or
(ii) Xx is a bond and
either
(j) R3 x is alkoxy of 1 to 4 carbon atoms or halogen of atomic number of from 9 to 35,
R4 x is hydrogen and, when R3 x is alkoxy of 1 to 4 carbon atoms, R3 x additionally may be alkoxy of 1 to 4 carbon atoms or, when R3 x is halogen of atomic number of from 9 to 35, R4 x additionally may be halogen of atomic number of from 9 to 35,
R1 x is hydrogen or methyl and
R2 x is CONRa Rb, wherein Ra and Rb are as defined above,
or
(jj) R3 x is hydroxy, cyano, carbamoyl or NHCORd, wherein Rd is as defined above,
R4 x is hydrogen and
R1 x and R2 x have the significances indicated above for R1 and R2,
with the proviso, that Xx is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain.
5. A compound of claim 1 of formula Ix' ##STR56## wherein A is as defined above,
Xx' is oxygen or sulfur and
R1 x' to R4 x' have the significances indicated above for R1 to R4,
with the proviso, that Xx' is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain.
6. A compound of claim 1 of formula Iu, ##STR57## wherein Ru is a group ##STR58## wherein A is as defined above,
R1 u, R2 u and R4 u have the significances indicated above for R1, R2 and R4 and
R3 u with the exception of hydrogen has the significances indicated above for R3,
with the provisos, that
(a) the phenyl ring is separated by at least two carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain and
(b) when R2 u is cyano, R1 u additionally may be alkyl of 3 to 7 carbon atoms,
7. A compound of claim 1 of formula Iu', ##STR59## wherein Ru' is a group ##STR60## wherein A is as defined above, R3 u' of 1 to 4 carbon atoms or halogen of atomic number of from 9 to 35,
R4 u' is hydrogen and, when R3 u' is alkoxy of 1 to 4 carbon atoms, R4 u' additionally may be alkoxy of 1 to 4 carbon atoms or, when R3 u' is halogen of atomic number of from 9 to 35, R4 u' additionally may be halogen of atomic number of from 9 to 35,
either
(i) R1 u' is hydrogen or methyl and R2 u' is cyano, COORc or CH2 ORe, wherein Rc and Re are as defined above,
or
(ii) either R1 u' is methyl and R2 u' is halogen of atomic number of from 17 to 35
or
R1 u' is halogen of atomic number of from 17 to 35 and R2 u' is hydrogen or methyl,
with the provisos, that
(a) the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain and
(b) when R2 u' is cyano, R1 u' additionally may be alkyl of 3 to 7 carbon atoms.
8. A compound according to claim 1 which is 1-(3-chloro-2-methylindol-4-yloxy)-3-(2-phenoxyethylamino)-2-propanol, or a pharmaceutically acceptable acid addition salt thereof.
9. A compound of claim 1 wherein R is --C(CH3)3, R1 is H and R2 is CN, or a pharmaceutically acceptable acid addition salt thereof.
10. A compound of claim 1 wherein R is ##STR61## R1 is H, and R2 is CN, or a pharmaceutically acceptable acid addition salt thereof.
11. A compound of claim 1 wherein R is ##STR62## R1 is H, and R2 is CN, or a pharmaceutically acceptable acid addition salt thereof.
12. A compound of claim 1 wherein R is ##STR63## R1 is H, and R2 is CN, or a pharmaceutically acceptable acid addition salt thereof.
13. A compound of claim 1 wherein R is ##STR64## R1 is H, and R2 is CONH2, or a pharmaceutically acceptable acid addition salt thereof.
14. A compound of claim 1 wherein R is ##STR65## R1 is H, and R2 is CONH2, or a pharmaceutically acceptable acid addition salt thereof.
15. A compound of claim 1 wherein R is ##STR66## R1 is H, and R2 is CONH2, or a pharmaceutically acceptable acid addition salt thereof.
16. A compound of claim 1 wherein R is ##STR67## R1 is H, and R2 is CONH2, or a pharmaceutically acceptable acid addition salt thereof.
17. A compound of claim 1 wherein R is ##STR68## R1 is H, and R2 is CONH2, or a pharmaceutically acceptable acid addition salt thereof.
18. A compound of claim 1 wherein R is ##STR69## R1 is H, and R2 is ##STR70## or a pharmaceutically acceptable acid addition salt thereof.
19. A compound of claim 1 wherein R is ##STR71## R1 is CH3, and R2 is CONH2, or a pharmaceutically acceptable acid addition salt thereof.
20. A compound of claim 1 wherein R is ##STR72## R1 is H, and R2 is COOCH(CH3)2, or a pharmaceutically acceptable acid addition salt thereof.
21. A compound of claim 1 wherein R is ##STR73## R1 is H, and R2 is COOCH(CH3)2, or a pharmaceutically acceptable acid addition salt thereof.
22. A compound of claim 1 wherein R is ##STR74## R1 is CH3, and R2 is COOCH2 CH3, or a pharmaceutically acceptable acid addition salt thereof.
23. A compound of claim 1 wherein R is ##STR75## R1 is CH3, and R2 is Cl, or a pharmaceutically acceptable acid addition salt thereof.
24. A compound of claim 1 wherein R is ##STR76## R1 is Cl, and R2 is CH3, or a pharmaceutically acceptable acid addition salt thereof.
25. A compound of claim 1 wherein R is ##STR77## R1 is CH3, and R2 is Br, or a pharmaceutically acceptable acid addition salt thereof.
26. A compound of claim 1 wherein R is ##STR78## R1 is Cl, and R2 is CH3, or a pharmaceutically acceptable acid addition salt thereof.
27. A compound of claim 1 wherein R is ##STR79## R1 is H, and R2 is CONHCH3, or a pharmaceutically acceptable acid addition salt thereof.
28. A compound of claim 1 wherein R is ##STR80## R1 is H, and R2 is CH2 OCH3, or a pharmaceutically acceptable acid addition salt thereof.
29. A compound of claim 1 wherein R is ##STR81## R1 is H, and R2 is CH2 OCH3, or a pharmaceutically acceptable acid addition salt thereof.
30. A compound of the formula ##STR82## wherein Rp is alkyl of 3 to 7 carbon atoms, and
R1 p is hydrogen or methyl,
or a pharmaceutically acceptable acid addition salt thereof.
31. A compound of the formula ##STR83## wherein R1 p is as defined in claim 30,
A is alkylene of 2 to 5 carbon atoms,
R3 p is hydroxy, alkoxy of 1 to 4 carbon atoms, halogen of atomic number from 9 to 35, cyano, carbamoyl or acetamido, and
R4 p is hydrogen and, when R3 p is alkoxy of 1 to 4 carbon atoms, R4 p additionally may be alkoxy of 1 to 4 carbon atoms, or when R3 p is halogen of atomic number of from 9 to 35, R4 p additionally may be halogen of atomic number of from 9 to 35,
with the proviso that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety, or a pharmaceutically acceptable acid addition salt thereof.
32. A compound of the formula ##STR84## wherein A, R1 p, R3 p and R4 p are as defined in claim 10, and
Ra and Rb are, independently, hydrogen or alkyl of 1 to 4 carbon atoms,
with the proviso that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3 -amino-2-hydroxypropoxy moiety, or a pharmaceutically acceptable acid addition salt thereof.
33. A compound of the formula ##STR85## wherein A, R1 pd and R2 pd are as defined in claim 34,
R3 p is hydroxy, alkoxy of 1 to 4 carbon atoms, halogen of atomic number of from 9 to 35, cyano, carbamoyl or acetamido, and
R4 p is hydrogen and, when R3 p is alkoxy of 1 to 4 carbon atoms, R4 p additionally may be alkoxy of 1 to 4 carbon atoms, or when R3 p is halogen of atomic number of from 9 to 35, R4 p additionally may be halogen of atomic number of from 9 to 35,
with the proviso that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety, or a pharmaceutically acceptable acid addition salt thereof.
34. A compound of the formula ##STR86## wherein A is as defined in claim 31,
either
(i) R1 pd is halogen of atomic number of from 17 to 35 and
R2 pd is hydrogen or methyl
or
(ii) R1 pd is methyl and R2 pd is halogen of atomic number of from 17 to 35,
R3 pd is hydrogen or has the significance defined above for R3 p in claim 31,
R4 pd is as defined in claim 31 for R4 p, and
Xp is oxygen or sulfur,
with the proviso that Xp is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety,
or a pharmaceutically acceptable acid addition salt thereof.
35. A compound of the formula ##STR87## wherein A is alkylene of 2 to 5 carbon atoms,
Xp is oxygen or sulfur,
R1 p is hydrogen or methyl, and
R3 pd and R4 pd are as defined in claim 34,
with the proviso that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety,
or a pharmaceutically acceptable acid addition salt thereof.
36. A compound of the formula ##STR88## wherein A, Xp, R1 p, R3 pd and R4 pd are as defined in claim 35,
and
Ra and Rb are, independently, hydrogen or alkyl of 1 to 4 carbon atoms,
with the proviso that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety,
or a pharmaceutically acceptable acid addition salt thereof.
37. A compound of the formula ##STR89## wherein A, Xp, R1 p, R3 pd and R4 pd are as defined in claim 35,
and
R2 pe is CH2 OH or COORc
wherein
Rc is hydrogen or alkyl of 1 to 4 carbon atoms,
with the proviso that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety,
or a pharmaceutically acceptable acid addition salt thereof.
38. A compound of the formula ##STR90## wherein A, R1 p, R2 pe, R3 pd and R4 pd are as defined in claim 37, with the proviso that the phenyl ring is separted by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety,
or a pharmaceutically acceptable acid addition salt thereof.
Description

The present invention relates to 1-(indol-4-yloxy)-3-amino-2-propanol derivatives.

In accordance with the invention there are provided compounds of formula I ##STR3## wherein R is a group ##STR4## wherein A is alkylene of 2 to 5 carbon atoms,

X is a bond, oxygen or sulfur,

R3 is hydrogen, hydroxy, alkoxy of 1 to 4 carbon atoms, halogen of atomic member of from 9 to 35, cyano, carbamoyl or a group NHCORd, wherein Rd is alkyl of 1 to 4 carbon atoms, and

R4 is hydrogen and, when R3 is alkoxy of 1 to 4 carbon atoms, R4 additionally may be alkoxy of 1 to 4 carbon atoms or, when R3 is halogen of atomic number of from 9 to 35, R4 additionally may be halogen of atomic number of from 9 to 35

either

(i) R1 is hydrogen or methyl and

R2 is cyano, CONRa Rb, COORc or CH2 ORe, wherein Ra, Rb, Rc and Re independently are hydrogen or alkyl of 1 to 4 carbon atoms,

or

(ii) either R1 is methyl and R2 is halogen of atomic number of from 17 to 35

or R1 is halogen of atomic number of from 17 to 35 and R2 is hydrogen or methyl,

with the provisos that

(a) X is separated from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain by at least 2 carbon atoms,

(b) when X is a bond, R3 is other than hydrogen and

(c) when R2 is cyano, R additionally may be alkyl of 3 to 7 carbon atoms.

R preferably is a group ##STR5## X preferably is a bond or oxygen. R3 preferably is hydrogen, hydroxy or alkoxy. R4 preferably is hydrogen or alkoxy. R1 preferably is hydrogen or halogen. R2 preferably is methyl, cyano or CONRa Rb. Ra, Rb and Re preferably are hydrogen. Rc preferably is alkyl.

Alkyl (except as indicated hereunder for R and Rc) and/or alkoxy preferably are of 1 or 2, especially of 1 carbon atom. When R is alkyl, it preferably is of 3 to 5 carbon atoms and preferably is branched, especially in the position α to the nitrogen atom to which it is bound. Interesting alkyl groups R are e.g. isopropyl, tert-butyl and 3-pentyl, especially tert-butyl. When Rc is alkyl, it preferably is of 1 to 3 carbon atoms; when it is of more than 2 carbon atoms, it preferably is branched, as e.g. in isopropyl.

Halogen preferably is bromine of chlorine, especially chlorine. A preferably is branched alkylene, especially in the position α to the nitrogen atom to which it is bound, e.g. the group ##STR6## or it is ethylene.

When R3 and R4 are hydrogen, X preferably is oxygen. When R3 is not hydrogen, X preferably is a bond.

When R3 is not hydrogen, it preferably is in the para position. When R4 is not hydrogen, it preferably is in the meta position. When R4 is alkoxy or halogen, it preferably is identical to R3.

A group of compounds of formula I are the compounds of formula Ix ##STR7## wherein Rx is a group ##STR8## wherein A is as defined above, either

(i) Xx is oxygen or sulfur and R1 x to R4 x have the significances indicated above for R1 to R4

or

(ii) Xx is a bond and

either

(j) R3 x is alkoxy of 1 to 4 carbon atoms or halogen of atomic number of from 9 to 35,

R4 x is hydrogen and, when R3 x is alkoxy of 1 to 4 carbon atoms, R4 x additionally may be alkoxy of 1 to 4 carbon atoms or, when R3 x is halogen of atomic number of from 9 to 35, R4 x additionally may be halogen of atomic number of from 9 to 35,

R1 x is hydrogen of methyl and

R2 x is CONRa Rb, wherein Ra and Rb are as defined above,

or

(jj) R3 x is hydroxy, cyano, carbamoyl or NHCORd, wherein Rd is as defined above,

R4 x is hydrogen and

R1 x and R2 x have the significances indicated above for R1 and R2,

with the proviso, that Xx is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain.

A group of compounds of formula Ix are the compounds of formula Ix' ##STR9## wherein A is as defined above,

Xx' is oxygen or sulfur and

R1 x' to R4 x' have the significances indicated above for R1 to R4,

with the proviso, that Xx' is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain.

In accordance with the invention, a compound of formula I may be obtained by a process comprising reacting a corresponding compound of formula II ##STR10## wherein R1 and R2 are as defined above and Ro is a group capable of reacting with an amine to give a 2-amino-1-hydroxyethyl group,

with a corresponding compound of formula III

R--NH2                                                III

wherein R is as defined above.

The present process is an amination by a primary amine. It may be effected in conventional manner for the production of analogous 3-amino-2-hydroxypropoxyaryl compounds. For example Ro may be a group of formula ##STR11## or a reactive derivative of this group, e.g. of formula --CH(OH)--CH2 Y, wherein Y is halogen, preferably chlorine or bromine, or a group Ry --SO2 --O, wherein Ry is phenyl, tolyl or lower alkyl. Y is especially chlorine. The reaction is effected preferably in an inert organic solvent, e.g. in an appropriate ether such as dioxane. Optionally an excess of a compound of formula III may be used as solvent. Alternatively the reaction may be effected in a fusion melt. Suitable reaction temperatures may be from about 20 to about 200 C., conveniently the reflux temperature of the reaction mixture when a solvent is present.

Free base forms of the compounds of formula I may be converted into salt forms, e.g. into acid addition salt forms, in conventional manner and vice versa. Suitable acids for salt formation include maleic, malonic and fumaric acid. When R3 is hydroxy or Rc is hydrogen, salts may be formed with strong bases, e.g. sodium hydroxide.

In the compounds of formula I, the carbon atom to which the hydroxy group is bound is asymmetrically substituted. The compounds may thus exist in the racemic form or in individual optical isomer form. The preferred optical isomer has the S configuration at the asymmetrically substituted carbon atom of the hydroxypropoxy side chain.

Individual optical isomer forms may be obtained in conventional manner, for example by using optically active starting materials or by fractional crystallisation using optically active acids.

In so far the preparation of any particular starting material is not particularly described, this may be effected in conventional manner. 4-Hydroxyindol-2-carbonitrile and 4-Hydroxy-3-methylindol-2-carbonitrile may be obtained by splitting off of a water molecule from the corresponding 2-carboxamide derivative, e.g. using titanium tetrachloride.

In the following examples all temperatures are in degrees Centigrade and are uncorrected.

EXAMPLE 1 1-(3-Chloro-2-methylindol-4-yloxy)-3-(2-phenoxyethylamino)-2-propanol

5 g 3-chloro-4-(2,3-epoxypropoxy)-2-methylindole, 4.3 g phenoxyethylamine and 75 ml dioxane are heated at 130 for 15 hours in an autoclave. The reaction mixture is allowed to cool down, the excess dioxane is evaporated in a vacuum produced by a waterpump and the excess amine is distilled off under high vacuum at 80. The reaction mixture is partitioned between aqueous tartaric acid solution and methylene chloride. The aqueous phase is made alkaline with conc. ammonia and extracted with methylene chloride. Evaporation of the organic phase yields the title compound (M.P. of the hydrogen malonate 135-137 after crystallization from methanol).

From the appropriate compound of formula II, wherein Rx is --CH(OH)--CH2 Cl, and the appropriate compound of formula III the following compounds of formula I may be obtained in analogous manner to Example 1:

__________________________________________________________________________ExampleNo.   R               R1                     R2                            M.P.__________________________________________________________________________ 2   C(CH3)3                 H  CN      f 259-261 3 ##STR12##       H  CN      hmi 166-169 4 ##STR13##       H  CN      hcl 88  (foam) 5 ##STR14##       H  CN      f 172-175 6 ##STR15##       H  CONH2                            b 198-200 7 ##STR16##       H  CONH2                            f 209-212 8 ##STR17##       H  CONH2                            hcl 111-113 9 ##STR18##       H  CONH2                            f 170-17310 ##STR19##       H  CONH2                            hcl 94  (foam)11 ##STR20##       H                     ##STR21##                            f 157-16012 ##STR22##       CH3                    CONH2                            f 236-23813 ##STR23##       H  COOCH(CH3)2                            b 121-12414 ##STR24##       H  COOCH(CH.sub. 3)2                            b 203-20515 ##STR25##       CH3                    COOCH2 CH3                            f 241-24316 ##STR26##       CH3                    Cl      b 129-13117 ##STR27##       Cl CH3                            hf 99  (sinters)18 ##STR28##       CH3                    Br      b 126-12819 ##STR29##       Cl CH3                            f 141-14320 ##STR30##       H  CONHCH3                            f 121-12421 ##STR31##       H  CH2 OCH3                            f 103-10622 ##STR32##       H  CH2 OCH3                            b 149-151__________________________________________________________________________ b = free form f = bis[base]fumarate hcl = hydrochloride hf = hydrogen fumarate hmi = hydrogen maleinate

The following compounds of formula I may also be obtained in a manner analogous to Example 1:

__________________________________________________________________________ExampleNo.    R               R1                      R2__________________________________________________________________________23 ##STR33##        Br H24 ##STR34##        CH3                     COOH25 ##STR35##        CH3                     CN26 ##STR36##        CH3                     CH2 OH27 ##STR37##        H                      ##STR38##__________________________________________________________________________

The compounds of formula I are useful because they exhibit pharmacological activity in animals.

The compounds of formula I possess cardiovascular adrenergic α- and β-blocking activity.

In particular, they inhibit α-adrenoceptors in isolated spiral strips of the Vena femoralis of dogs (E. Muller-Schweinitzer and E. Sturmer, Br. J. Pharmacol. [1974] 51, 441-446) and inhibit β-adrenoceptors in isolated spiral strips of the Arteria coronaria of dogs (T. J. Bucher et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 280 [1973] 153-160). These actions take place at a bath concentration of from about 10-9 to about 10-6 M. In the spontaneously beating guinea pig atrium (K. Saameli, Helv. Physiol. Acta 25 [1967] CR 219-CR 221) they inhibit the positive inotropic adrenaline effect at bath concentrations of from 0.005 to 2.5 mg/l.

The compounds are therefore useful as α- and β-blocking agents, e.g. for the therapy and possibly prophylaxis of diseases related to an adrenergic vasoconstriction, and of coronary diseases, especially of Angina pectoris. They are also useful for the treatment of diseases related to an inhibition of bowel motility, especially of paralytic ileus. In view of their antiarrhythmic activity they are also useful as antiarrhythmics.

The compounds of Example 1 to 19 exhibit particularly interesting activity as α- and β-blocker. The Example 10 compound exhibits particularly interesting activity as a β-blocker.

For these uses the dosage will, of course, vary depending on the compound employed, mode of administration and treatment desired. However, in general, satisfactory results are obtained when administered at a daily dosage of from about 0.01 mg to about 3 mg per kg animal body weight, conveniently given in divided doses 2 to 4 times a day or in sustained release form. For the larger mammals, the total daily dosage is in the range from about 20 to about 100 mg, and dosage forms suitable for oral administration comprise from about 5 mg to about 50 mg of the compounds admixed with a solid or liquid pharmaceutical carrier or diluent.

The compounds of formula I also exhibit antihypertensive activity.

This is indicated in standard tests, e.g. in the Grollman rat test [A. Grollman, Proc. Soc. Exp. Biol. and Med. 57 (1944) 102] on s.c. administration of from 0.1 to 10 mg/kg animal body weight of the compounds, and on p.o. administration of from 10 to 100 mg/kg.

The compounds are therefore useful as antihypertensive agents. Especially interesting in this indication is the compound of Example 1.

For this use the dosage will, of course, vary depending on the compound employed, mode of administration and treatment desired. However, in general, satisfactory results are obtained when administered at a daily dosage of from about 0.1 mg to about 10 mg per kg animal body weight, conveniently given in divided doses 2 to 4 times a day or in sustained release form. For the larger mammals, the total daily dosage is in the range from about 1 to about 50 mg, and dosage forms suitable for oral administration comprise from about 0.25 mg to about 25 mg of the compounds admixed with a solid or liquid pharmaceutical carrier or diluent.

The compounds of formula I also possess interesting metabolic activity.

In particular, they inhibit glycerol release and hyperglycemia stimulated by isoproterenol in standard tests.

Inhibition of glycerol release is e.g. indicated as follows:

(i) In vitro

Isolated fat cells are obtained from dog subcutaneous tissue, and from rat and guinea pig epididymal fat pads, in accordance with the method of M. Rodbell [J. Biol. Chem. 239, 375-380 (1964)]. Cells from one of the animals are dispersed in Krebs phosphate buffer containing 4% bovine serum albumin. 1 ml aliquots of the cell suspension in plastic incubation flasks are treated with the test substance at from about 0.1 to about 10 mg/liter and isoproterenol at 10-7 Molar. The glycerol release is determined in conventional manner, e.g. according to the method of S. Laurell et al, Helv. Chim. Acta 13, 317-322 (1966).

(ii) In vivo

Rats are fasted for 16 hours. A sub-cutaneous injection of 400 μg/kg of isoproterenol results in a glycerol concentration in the blood plasma of 400% the original value. This increased glycerol concentration remains constant for ca. 60 minutes and acts as a control value. The test substance is administered s.c. at a dose of from about 0.1 to about 10 mg/kg body weight 10 minutes before the isoproterenol injection, and the animals are decapitated 40 minutes after the isoproterenol injection. The glycerol concentration in the blood is calculated in conventional manner, e.g. using the conventional glycero-3-phosphate-dehydrogenase method [according S. Laurell et al; reference as mentioned above].

Inhibition of hyperglycemia is e.g. indicated as follows:

In the above-mentioned rat in vivo test the glucose concentration in the blood is determined in conventional manner, e.g. using the ferricyanide method. In the control animals the glucose concentration doubles after 40 minutes after isoproterenol administration. The compounds are administered s.c. at a dose of from about 0.1 to about 10 mg/kg animal body weight.

The compounds are therefore useful in the treatment of lipolysis in the blood and hyperglycemia induced by emotional stress, and are useful therefore for the treatment of, or prophylaxis of myocardial infarction and appetite induced by emotional stress.

Especially interesting in this indication are the compounds of Examples 2, 5 and 19, especially the compound of Example 5.

For these indications as metabolic inhibitors the dosage will, of course, vary depending on the compound employed, mode of administration and treatment desired. However, in general, satisfactory results are obtained when administered at a daily dosage of from about 0.01 mg to about 5 mg per kg animal body weight, conveniently given in divided doses 2 to 4 times a day or in sustained release form. For the larger mammals, the total daily dosage is in the range from about 0.1 to about 200 mg, and dosage forms suitable for oral administration comprise from about 0.025 mg to about 100 mg of the compounds admixed with a solid or liquid pharmaceutical carrier or diluent.

One group of compounds of formula I, i.e. the compounds of formula Iu ##STR39## wherein

Ru is a group ##STR40## wherein A is as defined above,

R1 u, R2 u and R4 u have the significances indicated above for R1, R2 and R4 and

R3 u with the exception of hydrogen has the significance indicated above for R3,

with the provisos, that

(a) the phenyl ring is separated by at least two carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain and

(b) when R2 u is cyano, R1 u additionally may be alkyl of 3 to 7 carbon atoms,

exhibit activities that are unexpectedly more interesting than those exhibited by known compounds of similar structure.

A preferred group of compounds of formula Iu are the compounds of formula Iu' ##STR41## wherein

Ru' is a group ##STR42## wherein A is as defined above,

R3 u' is alkoxy of 1 to 4 carbon atoms or halogen of atomic number of from 9 to 35,

R4 u' is hydrogen and, when R3 u' is alkoxy of 1 to 4 carbon atoms, R4 u' additionally may be alkoxy of 1 to 4 carbon atoms or, when R3 u' is halogen of atomic number of from 9 to 35, R4 u' additionally may be halogen of atomic number of from 9 to 35,

either

(i) R1 u' is hydrogen or methyl and

R2 u' is cyano, COORc or CH2 OR3, wherein Rc and Re are as defined above,

or

(ii) either R1 u' is methyl and R2 u' is halogen of atomic number of from 17 to 35

or R1 u' is halogen of atomic number of from 17 to 35 and R2 u' is hydrogen or methyl,

with the provisos, that

(a) the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy chain and

(b) when R2 u' is cyano, R1 u' additionally may be alkyl of 3 to 7 carbon atoms.

In general, the 2(S) optical isomers are more active than the 2(R) optical isomers in the cardiovascular β-blocking, metabolic and blood pressure lowering tests.

The compounds of formula I may be administered in pharmaceutically acceptable salt form. Such salt forms exhibit the same order of activity as the free forms and are readilly prepared in conventional manner. The present invention also provides a pharmaceutical composition comprising a compound of formula I, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutical carrier or diluent. Such compositions may be in the form of, for example, a solution or a tablet.

Further groups of compounds of formula I are the following:

(a) Compounds of formula Ipa ##STR43## wherein Rp is alkyl of 3 to 7 carbon atoms and

R1 p is hydrogen or methyl;

(b) compounds of formula Ipb ##STR44## wherein R1 p and A are as defined above

R3 p is hydroxy, alkoxy of 1 to 4 carbon atoms, halogen of atomic number of from 9 to 35, cyano, carbamoyl or acetamido and

R4 p is hydrogen and, when R3 p is alkoxy of 1 to 4 carbon atoms, R4 p additionally may be alkoxy of 1 to 4 carbon atoms, or when R3 p is halogen of atomic number of from 9 to 35, R4 p additionally may be halogen of atomic number of from 9 to 35,

with the proviso that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety;

(c) compounds of formula Ipc ##STR45## wherein

A, R1 p, R3 p, R4 p, Ra and Rb are as defined above,

with the proviso that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety;

(d) compounds of formula Ipd ##STR46## wherein

A is as defined above,

either (i) R1 pd is halogen of atomic number of from 17 to 35 and R2 pd is hydrogen or methyl

or (ii) R1 pd is methyl and R2 pd is halogen of atomic number of from 17 to 35,

R3 pd is hydrogen or has the significances indicated above for R3 p

R4 pd has the significances indicated above for R4 p and

Xp is oxygen or sulfur,

with the proviso that Xp is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety;

(e) compounds of formula Ipe ##STR47## wherein

A, Xp, R1 p, R3 pd and R4 pd are as defined above, with the proviso that the phenyl ring is separated by at least 2 carbon atoms for the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety;

(f) compounds of formula Ipf ##STR48## wherein

A, Xp, R1 p, R3 pd, R4 pd, Ra and Rb are as defined above, with the proviso that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety;

(g) compounds of formula Ipg ##STR49## wherein

A, Xp, R1 p, R3 pd and R4 pd are as defined above and R2 pe is CH2 OH or COORc, wherein Rc is as defined above, with the proviso, that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety;

(h) compounds of formula Iph ##STR50## wherein A, R1 p, R2 pe, R3 pd and R4 pd are as defined above, with the proviso, that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety;

(i) compounds of formula Ipi ##STR51## wherein A, R1 pd, R2 pd, R3 p and R4 p are as defined above, with the proviso, that the phenyl ring is separated by at least 2 carbon atoms from the nitrogen atom of the 3-amino-2-hydroxypropoxy moiety.

In a 1st group of compounds X is a bond.

In a 2nd group of compounds X is oxygen.

In a 3rd group of compounds X is sulfur.

In a 4th group of compounds R3 is other than NHCORd.

In a 5th group of compounds R3 is NHCORd.

In a 6th group of compounds R2 is cyano.

In a 7th group of compounds R2 is CONRa Rb.

In a 8th group of compounds R2 is COORc.

In a 9th group of compounds R2 is CH2 ORe.

In a 10th group of compounds R2 is halogen.

In a 11th group of compounds R2 is hydrogen.

In a 12th group of compounds R2 is methyl.

In a 13th group of compounds R is alkyl.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3340266 *Jul 20, 1964Sep 5, 1967Ici Ltd(3-amino-2-hydroxypropoxy)-benzoheterocyclic derivatives
US3432545 *Aug 18, 1964Mar 11, 1969Ici Ltd3-aryloxy-1-amino-2-propanols and salts thereof
US3696120 *Jul 28, 1970Oct 3, 1972Franz Troxler4-(2-hydroxy-3-amino propoxy)-indole derivatives
US3696121 *Jul 17, 1970Oct 3, 1972Sandoz Ltd4-(2-hydroxy-3-amino propoxy)-indole derivatives
US3699123 *Mar 16, 1971Oct 17, 1972Sandoz Ltd4-(3-amino-2-hydroxy-propoxy) indole derivatives
US3705907 *Jun 15, 1970Dec 12, 1972Sandoz Ltd4-(2-hydroxy)-3-aminopropoxy)-indole derivatives
US3751429 *Sep 24, 1971Aug 7, 1973Sandoz Ltd4-(3-amino-2-substituted propoxy)indole derivatives
Non-Patent Citations
Reference
1 *Cram et al., Organic Chem. 2nd Ed. McGraw Hill N. Y. (1964), pp. 255 & 256.
2 *Suvorov et al., Chem. Abst. 80, 70637p (1974).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4346093 *Jan 31, 1980Aug 24, 1982Boehringer Mannheim GmbhCardiovascular disorders
US4642309 *Sep 26, 1985Feb 10, 1987Boehringer Mannheim GmbhIndolin-2-one derivatives preparation thereof and intermediates for the preparation thereof
US5229412 *Mar 25, 1988Jul 20, 1993The Board Of Trustees Of The Leland Stanford Junior UniversityAdministering carrier with anxiolytic derivatives of N-(3-/4-indolyloxy/-2-hydroxypropyl)-1,8-diamino-p-menthane
US6022894 *Apr 4, 1997Feb 8, 2000Nps Pharmaceuticals, Inc.Method of using calcilytic compounds
US6046227 *Dec 4, 1998Apr 4, 2000Eli Lilly And CompanyUseful in the treatment of type ii diabetes and obesity; a substituted pyrazine compound
US6140352 *Aug 28, 1997Oct 31, 2000Eli Lilly And CompanyCarbazolyl-substituted ethanolamines as selective β-3 agonists
US6265581Apr 17, 2000Jul 24, 2001Eli Lilly And CompanyReacting specified epoxide and amine, reacting product with acid to form acid addition salt
US6413991Jun 30, 2000Jul 2, 2002Eli Lilly And CompanyAntidiabetic agents; dietetics
US6432656Aug 6, 1999Aug 13, 2002Nps Pharmaceuticals, Inc.Detection of calcilytic compound for calcium receptor bearing cell
US6521667Aug 11, 1998Feb 18, 2003Nps Pharmaceuticals, Inc.Calcilytic compounds
US6617347Nov 18, 1999Sep 9, 2003Eli Lilly And CompanySelective β3 adrenergic agonists
US6686372Apr 10, 2002Feb 3, 2004Eli Lilly And CompanySelective β3 adrenergic agonists
US6818660Oct 19, 2001Nov 16, 2004Nps Pharmaceuticals, Inc.Calcilytic compounds
US7041684Oct 27, 2003May 9, 2006Eli Lilly And Company4-[2-Hydroxy-3-([4-(5-carbamoyl-2-pyridyloxy)phenyl]-2-methylpropylamino)propoxy]carbazole and salts;treating obesity; antidiabetic agent for non-insulin dependent diabetes (Type II);
US7202261Jul 21, 2004Apr 10, 2007Nps Pharmaceuticals, Inc.Calcilytic compounds
CN1989129BJul 14, 2005Nov 10, 2010伊莱利利公司A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt
EP0827746A1 *Aug 27, 1997Mar 11, 1998Eli Lilly And CompanyCarbazole analogues as selective B3 adrenergic agonists
WO1997010825A1 *Sep 20, 1996Mar 27, 1997Michael G BellSELECTIVE β3 ADRENERGIC AGONISTS
Classifications
U.S. Classification514/415, 548/492, 548/467, 548/505, 548/503, 514/419
International ClassificationC07D209/12, C07D209/30, C07D209/42
Cooperative ClassificationC07D209/30, C07D209/42, C07D209/12
European ClassificationC07D209/42, C07D209/30, C07D209/12
Legal Events
DateCodeEventDescription
Mar 29, 1982ASAssignment
Owner name: FIDELITY UNION TRUST COMPANY, EXECUTIVE TRUSTEE UN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SANDOZ LTD (A/K/A SANDOZ A.G.);REEL/FRAME:003957/0944
Effective date: 19781108